Program
ARO-DIMERPA
Its studies are mostly in Hyperlipoproteinemia Type II, led by Arrowhead Pharmaceuticals.
Furthest: phase 2, since Oct 30, 20251 company-led study, 1 open or runningNext primary completion: Jul 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Arrowhead Pharmaceuticals | 11 open or running | phase 2since Oct 30, 2025 | Oct 30, 2025 | Jul 2027phase 2 · NCT07223658 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 30, 2025First study: phase 2 study in Hyperlipoproteinemia Type IIFirst studyNCT07223658 · 78 planned · Australia, Canada, Georgia and more
Ahead
- Jul 2027Primary completion: phase 2 study in Hyperlipoproteinemia Type IINCT07223658
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07223658Hyperlipoproteinemia Type II · Australia, Canada, Georgia and more | 2 | Recruiting | Jul 2027 | 78 |
How it is read
Names in the registry
- “ARO-DIMERPA”, 1 entry
Conditions, from the studies’ own filings
- Hyperlipoproteinemia Type II, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.